RU2020126278A3 - - Google Patents

Download PDF

Info

Publication number
RU2020126278A3
RU2020126278A3 RU2020126278A RU2020126278A RU2020126278A3 RU 2020126278 A3 RU2020126278 A3 RU 2020126278A3 RU 2020126278 A RU2020126278 A RU 2020126278A RU 2020126278 A RU2020126278 A RU 2020126278A RU 2020126278 A3 RU2020126278 A3 RU 2020126278A3
Authority
RU
Russia
Application number
RU2020126278A
Other languages
Russian (ru)
Other versions
RU2020126278A (ru
RU2797409C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020126278A3 publication Critical patent/RU2020126278A3/ru
Publication of RU2020126278A publication Critical patent/RU2020126278A/ru
Application granted granted Critical
Publication of RU2797409C2 publication Critical patent/RU2797409C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2020126278A 2018-02-06 2019-02-06 Ингибитор fap RU2797409C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18155419.7 2018-02-06
EP18155420 2018-02-06
EP18155420.5 2018-02-06
EP18155419 2018-02-06
EP18199641.4 2018-10-10
EP18199641 2018-10-10
PCT/EP2019/052952 WO2019154886A1 (en) 2018-02-06 2019-02-06 Fap inhibitor

Publications (3)

Publication Number Publication Date
RU2020126278A3 true RU2020126278A3 (cg-RX-API-DMAC10.html) 2022-03-09
RU2020126278A RU2020126278A (ru) 2022-03-09
RU2797409C2 RU2797409C2 (ru) 2023-06-05

Family

ID=

Also Published As

Publication number Publication date
IL276594B1 (en) 2023-07-01
SG11202007180QA (en) 2020-08-28
JP2021512949A (ja) 2021-05-20
BR112020015985A2 (pt) 2020-12-15
EP3749663A1 (en) 2020-12-16
AU2023201120A1 (en) 2023-03-30
PH12020551205A1 (en) 2021-04-19
IL276594B2 (en) 2023-11-01
AU2025203815A1 (en) 2025-06-12
KR20250021601A (ko) 2025-02-13
MX2020008271A (es) 2020-11-09
AU2025203824A1 (en) 2025-06-12
CN118146196A (zh) 2024-06-07
IL276594A (en) 2020-09-30
RU2020126278A (ru) 2022-03-09
CO2020009625A2 (es) 2020-08-21
AU2019219057B2 (en) 2022-11-24
AU2025203825A1 (en) 2025-06-12
US20230112012A1 (en) 2023-04-13
CN111699181A (zh) 2020-09-22
WO2019154886A1 (en) 2019-08-15
KR20250016523A (ko) 2025-02-03
US20250127937A1 (en) 2025-04-24
AU2023201120B2 (en) 2025-02-27
CL2020002026A1 (es) 2020-11-27
AU2019219057A1 (en) 2020-07-09
KR20200123148A (ko) 2020-10-28
KR102794330B1 (ko) 2025-04-11
CA3088326A1 (en) 2019-08-15
JP2025165981A (ja) 2025-11-05
US20210038749A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
BR112021000792B8 (cg-RX-API-DMAC10.html)
AT524874A5 (cg-RX-API-DMAC10.html)
AT524834A2 (cg-RX-API-DMAC10.html)
AU2018438767B1 (cg-RX-API-DMAC10.html)
AT521543A3 (cg-RX-API-DMAC10.html)
AT524961A5 (cg-RX-API-DMAC10.html)
AT524266A2 (cg-RX-API-DMAC10.html)
BR102019026286B1 (pt) Método e aparelho para o avanço de produtos a serem moldados
BR102019025884B1 (pt) Sistema de segurança aprimorado para máquinas de operação de autopropulsão
BR102019023514B1 (pt) Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna
BR112021001434B1 (pt) Aço com alto teor de manganês e método de produção do mesmo
BR112021001374B1 (pt) Composição farmacêutica para o tratamento da hipertensão e seu uso
BR112021001128B1 (pt) Composição de cimento para impressão 3d, método de impressão 3d, kit para a preparação de uma composição de cimento para impressão 3d e método de impressão 3d implementando o kit
BR112021001186B1 (pt) Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos
BR112020023795B1 (pt) Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção
BR112021000922B1 (pt) Tela de filtro, e, método para purificar água de alimentação
BR112020026077B1 (pt) Recipiente com estrutura encaixável
BR112020023832B1 (pt) Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral
BR112020024987B1 (pt) Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico
BR112020023823B1 (pt) Distribuidor
BR112020022482B1 (pt) Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico
BR112020022658B1 (pt) Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido
BR112020022516B1 (pt) Processo para degomagem enzimática de óleo
BR112020021042B1 (pt) Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas
BR112020020812B1 (pt) Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado